




# Executive Summary

---

- Medicinal Nanoengineering® enables enhanced trafficking of drugs to tumors, resulting in better efficacy and therapeutic index
- Demonstrated to improve TI of cytotoxic agents and molecularly targeted cancer drugs
- Physicochemical and biopharmaceutical properties of many oncology compounds (marketed and developmental) are extremely compatible with the BIND platform

# BIND Medicinal Nanoengineering platform

## BIND Targeted Nanoparticle



- Controlled release polymers
- API
- Stealth and protective layer
- Targeting ligand

## Features


- High drug concentrations in target tissues
  - Long circulating half-life
  - Tunable biodistribution
  - Immune system evasion
  - Dual targeting mechanisms
- Unmodified API
- Wide range of APIs
- FDA approved, biocompatible, biodegradable polymers
- Robust, reproducible and scalable manufacturing

## Best in class Drugs

- Expanded Therapeutic Index*
- Enabling of Difficult APIs*
- Expanded Indications and Lifecycle*
- High Barriers to Generics*
- Clear Regulatory Path*
- Low COGS*


# Our first clinical stage product: BIND-014

- **BIND-014 goal: Best-in-class taxane**
- **Target: PSMA**
  - Clinically validated target with widespread solid tumor expression
  - Prostate cancer cell surface (95% of patients)
  - Non-prostate solid tumor neovasculature (> 80% of breast, colorectal, renal and bladder cancer patients)
- **Payload: Docetaxel**
  - Approved for prostate, breast, lung, gastric, and head/neck cancers
- **Development pathway**
  - Well-defined 505(b)(2) registration pathway
  - Ongoing Phase 1 clinical study in solid tumors




# BIND-014 and Taxotere PK



## Tumor Bearing Mice




## Rat GLP tox PK




## Monkeys







# BIND-014 and Taxotere tumor targeting



**Breast (MX-1) Tumor Targeting (24 h)**



# BIND-014 efficacy and tolerability





# BIND-014 Phase 1 clinical study


---

- **BIND-014-001**
  - A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014, Given by IV Infusion to Patients with Advanced or Metastatic Cancer
- **Investigators:** Dan Von Hoff (Tgen), Pat LoRusso (Karmanos), Peter Eisenberg (Marin Cancer Center)
- **Primary objective**
  - Assess the dose limiting toxicities of BIND-014, determine the maximum tolerated dose when given once every three weeks, and select a dose for use in Phase 2 clinical studies
- **Secondary objectives**
  - Characterize the PK profile of BIND-014
  - Assess any preliminary evidence of anti-tumor activity




# Medicinal nanoengineering of partner kinase inhibitor


## In vitro release




## PK in rats




## Enhanced tumor accumulation



## Efficacy at lower dose



# BIND Medicinal Nanoengineering platform



# BIND overview

BIND was founded in 2006 by two pioneering academic investigators...

**Robert Langer, ScD** – MIT, David H. Koch Institute Professor

**Omid Farokhzad, MD** – Harvard Medical School, Associate Professor

...is led by an experienced team of successful entrepreneurs and drug developers...

**Scott Minick – President & CEO**

ARCH Venture Partners, SEQUUS, Baxter, Lilly

**Jeff Hrkach, PhD – SVP, Pharm Sci**

Momenta, Alkermes, AIR



**Jim Wright, PhD – CSO**

Infinity, Millennium, Alkermes, BI

**Steve Zale, PhD – VP, Development**

Alkermes, Sepracor



**Ed Schnipper, MD – CMO**

ALZA, SEQUUS, Roche

**Paul Burgess, JD – VP, IP**

J&J, TransForm, Genetics Institute





**Andrea Franz – CFO**

Franz Assoc., ESS, Groundwater Technologies

**Dan Koerwer – Head, Market & Bus. Dev.**

Eidetica Biopharma, Biogen Idec

...and has been backed by leading VC firms and US government



# BIND high-precision therapeutics through Medicinal Nanoengineering



MIT Technology Review 2010  
50 Most Innovative Companies



MIT Technology Review 2011  
50 Most Innovative Companies

THE WALL STREET JOURNAL.

WEDNESDAY, SEPTEMBER 12, 2007

© 2007, Dow Jones & Company, Inc. All Rights Reserved

*Betting on Nanotech Therapies*



**Magic Nano-Bullets**

Advances in nanotechnology could make drug delivery far more accurate and effective



**Cancer treatment dodges immune system**